third quarter 2026
Filed Nov 3, 2026Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Third-quarter revenue declined 41% to $7.6 million and non-GAAP adjusted EBITDA loss widened to $12.2 million, while the Anaphylm NDA resubmission was accepted with a March 16, 2027 PDUFA goal date and full-year 2026 guidance was maintained.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues, three months ended September 30, 2026GAAP | $7.6M | – | 41% decrease |
| Manufacture and supply revenue, three months ended September 30, 2026GAAP | $6.7M | – | – |
| License and royalty revenue, three months ended September 30, 2026GAAP | $800K | – | – |
| Manufacture and supply expense, three months ended September 30, 2026GAAP | $3.61M | – | – |
| Gross Margin on total revenue, three months ended September 30, 2026GAAP | 52 % | – | – |
| Non-GAAP adjusted manufacture and supply expenses, three months ended September 30, 2026non-GAAP | $3.40M | – | – |
| Non-GAAP Gross Margin on total revenue, three months ended September 30, 2026non-GAAP | 55 % | – | – |
| Research and development expenses, three months ended September 30, 2026GAAP | $4.3M | – | – |
| Non-GAAP adjusted research and development expenses, three months ended September 30, 2026non-GAAP | $3.92M | – | – |
| Selling, general and administrative expenses, three months ended September 30, 2026GAAP | $14.2M | – | – |
| Non-GAAP adjusted selling, general and administrative expenses, three months ended September 30, 2026non-GAAP | $12.43M | – | – |
| Total costs and expenses, three months ended September 30, 2026GAAP | $22.03M | – | – |
| Non-GAAP adjusted costs and expenses, three months ended September 30, 2026non-GAAP | $19.74M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$14.47M | – | – |
| Interest expense, three months ended September 30, 2026GAAP | −$1.84M | – | – |
| Interest expense related to royalty obligations, three months ended September 30, 2026GAAP | −$973K | – | – |
| Interest expense related to the sale of future revenue, three months ended September 30, 2026GAAP | −$62K | – | – |
| Interest income and other income, net, three months ended September 30, 2026GAAP | $853K | – | – |
| Net loss before income taxes, three months ended September 30, 2026GAAP | −$16.50M | – | – |
| Net loss, three months ended September 30, 2026GAAP | $16.5M | – | – |
| Basic and diluted loss per share, three months ended September 30, 2026GAAP | $0.13 for both basic and diluted loss per share | – | – |
| Weighted average common shares outstanding, basic and diluted, three months ended September 30, 2026GAAP | 125,548,783 (in shares) | – | – |
| Non-GAAP adjusted EBITDA loss, three months ended September 30, 2026non-GAAP | $12.2M | – | – |
| Non-GAAP adjusted EBITDA excluding Non-GAAP adjusted R&D expenses, three months ended September 30, 2026non-GAAP | −$8.27M | – | – |
| Revenues, nine months ended September 30, 2026GAAP | $35.82M | – | – |
| Gross Margin on total revenue, nine months ended September 30, 2026GAAP | 69 % | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −$26.90M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$47.42M | – | – |
| Basic and diluted loss per share, nine months ended September 30, 2026GAAP | $(0.38) (in dollars per share) | – | – |
| Non-GAAP adjusted EBITDA, nine months ended September 30, 2026non-GAAP | −$19.15M | – | – |
| Non-GAAP Gross Margin on total revenue, nine months ended September 30, 2026non-GAAP | 71 % | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Manufacture and supply revenueDecreases in Suboxone revenues due to timing of product orders, partially offset by higher Ondif revenues. | $6.7M | – | – |
| License and royalty revenueLower estimated royalty revenues. | $800K | – | – |
full-year 2026 outlook
- Revenue$46 to $50 (in millions)
- NoteNon-GAAP adjusted EBITDA loss (in millions) $35 to $30
What drove it
- The 41% decrease in total revenues was primarily driven by the quarterly fluctuation of Suboxone product orders.
- The Company manufactured approximately 26 million doses in the third quarter 2026, compared to approximately 44 million doses in the third quarter 2025.
- On a year-to-date basis through September, the Company manufactured approximately 107 million doses in 2026 compared to approximately 108 million doses in the same period in 2025.
- Research and development expense declined primarily due to lower share-based compensation, partially offset by higher clinical trial costs from the human factors validation study and PK study completed for the Anaphylm NDA resubmission.
- Selling, general and administrative expense declined primarily due to lower legal fees of approximately $1.5 million, lower commercial spending of approximately $1.4 million, and lower regulatory expenses related to Anaphylm of approximately $0.6 million.
- In October 2026, Aquestive granted Eton Pharmaceuticals, Inc. exclusive U.S. commercialization rights to Libervant and received a $10 million upfront payment.
Concerns
- Revenue fell to $7.6 million from $12.8 million as Suboxone product ordering timing reduced manufacture and supply revenue.
- Non-GAAP adjusted EBITDA loss widened to $12.2 million from $8.6 million.
- Net loss increased to $16.5 million from $15.4 million.
- Anaphylm approval remains subject to FDA review, with a PDUFA goal date of March 16, 2027.
- The filing identifies risks including eroding market share for Suboxone® and potential FDA requests for additional information, analyses, studies or inspections for Anaphylm.
What to watch
- FDA review of the Anaphylm Class 2 NDA resubmission ahead of the March 16, 2027 PDUFA goal date.
- Expected Health Canada submission in Q4 2026 and planned European Union filing in Q1 2027 for Anaphylm.
- Additional AQST-108 clinical work expected to begin in the first quarter of 2027.
- Final FDA action for Libervant patients twelve years of age and older, with a PDUFA goal date of March 23, 2027.
- FDA review of the Type 9 NDA for Libervant patients six to eleven years of age, with a PDUFA goal date of March 29, 2027.
- Execution of Eton Pharmaceuticals’ U.S. commercialization of Libervant and potential contingent milestone and royalty payments.
Balance sheet and cash flow
- Cash and cash equivalents were $90.3 million as of September 30, 2026.
- Cash and cash equivalents were $ 90,349 (In thousands) at September 30, 2026, compared with $ 121,169 (In thousands) at December 31, 2025.
- Debt, current was $ 33 (In thousands) at September 30, 2026, compared with $ 9,994 (In thousands) at December 31, 2025.
- Debt, long-term, net was $ 50,757 (In thousands) at September 30, 2026, compared with $ 27,519 (In thousands) at December 31, 2025.
- Royalty obligations, net were $ 28,702 (In thousands) at September 30, 2026, compared with $ 25,941 (In thousands) at December 31, 2025.
- Liability related to the sale of future revenue, net was $ 61,192 (In thousands) at September 30, 2026, compared with $ 62,023 (In thousands) at December 31, 2025.
Analysis
Aquestive reported a weaker third quarter on its existing commercial business. Total revenues decreased to $7.6 million from $12.8 million, a 41% decrease that the company attributed primarily to quarterly fluctuation in Suboxone product orders. Manufacture and supply revenue decreased to $6.7 million from $11.5 million, while license and royalty revenue decreased to $0.8 million from $1.0 million. Manufacturing volume was approximately 26 million doses, compared with approximately 44 million doses in the prior-year quarter.
The lower revenue base pressured profitability. GAAP gross margin on total revenue was 52%, compared with 65%, and non-GAAP gross margin was 55%, compared with 67%. The operating loss was $(14,469) (In thousands), compared with $(11,479) (In thousands). Net loss was $16.5 million, or $0.13 for both basic and diluted loss per share, compared with $15.4 million, or $0.14 for both basic and diluted loss per share. Non-GAAP adjusted EBITDA loss widened to $12.2 million from $8.6 million.
Cost control partly offset the revenue decline. Research and development expenses decreased to $4.3 million from $4.5 million, reflecting lower share-based compensation partly offset by higher clinical trial costs for Anaphylm studies. Selling, general and administrative expenses decreased to $14.2 million from $15.3 million, driven by lower legal fees, commercial spending and Anaphylm regulatory expenses, partly offset by higher personnel, share-based compensation, consulting and outside-services expenses. For the nine months ended September 30, 2026, revenues were $35,822 (In thousands) versus $31,530 (In thousands), while net loss was $(47,417) (In thousands) versus $(51,924) (In thousands).
The central business development was FDA acceptance of the Anaphylm NDA resubmission as a Class 2 response, with a March 16, 2027 PDUFA goal date. The company is progressing launch preparation, expects a Health Canada submission in Q4 2026 and plans an EU filing in Q1 2027. In a separate commercial development, Eton received exclusive U.S. commercialization rights to Libervant, paid Aquestive a $10 million upfront payment, and may generate up to $47.5 million in contingent regulatory and sales-based milestones plus mid-teens royalties on net sales. Aquestive remains the exclusive manufacturer and supplier under a 20-year supply agreement.
Liquidity stood at $90.3 million of cash and cash equivalents as of September 30, 2026, compared with $ 121,169 (In thousands) at December 31, 2025. Long-term debt, net was $ 50,757 (In thousands), and the liability related to the sale of future revenue, net was $ 61,192 (In thousands). Full-year 2026 guidance was unchanged at total revenue of $46 to $50 (in millions) and non-GAAP adjusted EBITDA loss of $35 to $30 (in millions).
Management, verbatim
With a PDUFA goal date of March 16, 2027, we believe we have a clear path to making Anaphylm available to patients and caregivers, if approved.
Daniel Barber, President and Chief Executive Officer
Not in the filing
stated, not guessed- Previous-period outlook was not provided, so comparison of actual results with prior guidance is unavailable.
- Quarterly operating cash flow was not reported.
- Quarterly free cash flow was not reported.
- Share repurchases, dividends and other capital-return activity were not reported.
- Total debt as a single line item was not reported; current debt and long-term debt, net were reported separately.
- A GAAP tax rate was not reported.
- Quarter-over-quarter comparisons were not reported for the financial metrics.
- Separate reported business-segment revenue beyond manufacture and supply revenue and license and royalty revenue was not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.